Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

1. Efficacy and Safety of Metformin for Obesity: A Systematic Review

Efficacy and Safety of Metformin for Obesity: A Systematic Review Efficacy and Safety of Metformin for Obesity: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save Email Send to Display (...) Format Share Permalink Copy Page navigation Review Pediatrics Actions . 2021 Mar;147(3):e20201610. doi: 10.1542/peds.2020-1610. Efficacy and Safety of Metformin for Obesity: A Systematic Review , , , , , Affiliations Expand Affiliations 1 Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. 2 Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. 3 Division of Endocrinology, Jewish General Hospital

2021 EvidenceUpdates

2. Rapid Changes in Serum Testosterone in Men with Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin

Rapid Changes in Serum Testosterone in Men with Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation (...) of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Apr;44(4):1059-1061. doi: 10.2337/dc20-1558. Epub 2021 Feb 3. Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin , , , , , , , , Affiliations Expand Affiliations 1 Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Jiangsu, China. 2

2021 EvidenceUpdates

3. Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes Full Text available with Trip Pro

Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) navigation Diabetes Obes Metab Actions . 2020 Nov 25. doi: 10.1111/dom.14266. Online ahead of print. Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes , , , , , , , Affiliations Expand Affiliations 1 Department of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 2 Barbara Davis Center

2021 EvidenceUpdates

4. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study Full Text available with Trip Pro

A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) : Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Mar;23(3):811-821. doi: 10.1111/dom.14288. Epub 2021 Jan 8. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study

2021 EvidenceUpdates

5. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review

SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review , , , , , , , , , Affiliations Expand Affiliations 1 Cardiology Department, University Hospital La Paz, Madrid, Spain. 2 Cardiology Department, University Hospital Ramon y Cajal, Madrid, Spain. 3 Cardiology Department, Hospital Arnau de Vilanova, Valencia, Spain. 4 Cardiology Department, Hospital Son Llàtzer, Palma de

2021 EvidenceUpdates

6. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study Full Text available with Trip Pro

Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) /dom.14263. Online ahead of print. Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study , , , , , , , , , Affiliations Expand Affiliations 1 Department of Hepatology, Nanpuh Hospital, Kagoshima, Japan. 2 Department of Internal Medicine, Kagoshima Kouseiren Hospital, Kagoshima, Japan. 3 Jiaikai Clinic, Kagoshima, Japan. 4 Uenomachi-Kajiya Clinic, Kagoshima, Japan. 5 Tempozan Naika Medical Clinic, Kagoshima, Japan

2021 EvidenceUpdates

7. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes Full Text available with Trip Pro

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Metab Actions . 2020 Oct 20. doi: 10.1111/dom.14234. Online ahead of print. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes , , , , , , , Affiliations Expand Affiliations 1 Yale University School of Medicine, New Haven, Connecticut, USA. 2 Diabetes Research Centre, University of Leicester, Leicester, UK. 3 Boehringer Ingelheim International GmbH, Ingelheim, Germany. 4 Boehringer Ingelheim

2020 EvidenceUpdates

8. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes Full Text available with Trip Pro

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) . Online ahead of print. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes , , , , , , , , , , , , Affiliations Expand Affiliations 1 George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia. 2 University of New South Wales, Sydney, New South Wales, Australia. 3 Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia. 4 Sydney Medical School, University of Sydney, Sydney

2020 EvidenceUpdates

9. Efficacy of metformin in patients with breast cancer receiving chemotherapy or endocrine therapy:Systematic review and meta-analysis (protocol) v2 (protocols.io.bmzak72e) Full Text available with Trip Pro

Efficacy of metformin in patients with breast cancer receiving chemotherapy or endocrine therapy:Systematic review and meta-analysis (protocol) v2 (protocols.io.bmzak72e) Efficacy of metformin in patients with breast cancer receiving chemotherapy or endocrine therapy:Systematic review and meta-analysis (protocol) protocols.io

2020 protocols.io

10. Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial Full Text available with Trip Pro

Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) navigation Diabetes Obes Metab Actions . 2020 Aug 3. doi: 10.1111/dom.14163. Online ahead of print. Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes

2020 EvidenceUpdates

11. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial

Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) : ( ) Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2020 Oct;8(10):834-844. doi: 10.1016/S2213-8587(20)30310-7. Metformin

2020 EvidenceUpdates

12. Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) . 2020 Aug 3;3(8):e2011995. doi: 10.1001/jamanetworkopen.2020.11995. Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis , , , , Affiliations Expand Affiliations 1 Women's Reproductive Health Research Key Laboratory of Zhejiang Province, Women's Hospital, Department of Reproductive Endocrinology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 2 Key Laboratory

2020 EvidenceUpdates

13. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study Full Text available with Trip Pro

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Aug 14;dc201104. doi: 10.2337/dc20-1104. Online ahead of print. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

14. Metformin May Block the Way Breast Cancer Metastasis: A Meta-analysis and Mechanism Review Full Text available with Trip Pro

Metformin May Block the Way Breast Cancer Metastasis: A Meta-analysis and Mechanism Review Metformin May Block the Way Breast Cancer Metastasis: A Meta-analysis and Mechanism Review | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement (...) of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Metformin May Block the Way Breast Cancer Metastasis: A Meta-analysis and Mechanism Review Ming Yang, Yueyuan Wang, Zhihao Zhang, Jingyu Peng, Xiao Xie, Xue Wei Ming Yang Department of Breast Surgery, The First Hospital of Jilin University, Changchun 130021, People’s Republic of China Corresponding Author ORCiD: https://orcid.org/0000-0002-4901-840X Yueyuan Wang Jilin

2020 Research Square

15. Use of metformin hydrochloride in gestational diabetes: a systematic review Full Text available with Trip Pro

Use of metformin hydrochloride in gestational diabetes: a systematic review Use of metformin hydrochloride in gestational diabetes: a systematic review | Research, Society and Development Open Menu Search Search / / / Review Article Jéssica Costa de Oliveira Faculdade de Enfermagem Nova Esperança de Mossoró Luanne Eugênia Nunes Faculdade de Enfermagem Nova Esperança de Mossoró Franciso Ernesto de Souza Neto Faculdade de Enfermagem Nova Esperança de Mossoró Rosueti Diógenes de Oliveira-Filho (...) Faculdade de Enfermagem Nova Esperança de Mossoró DOI: Keywords: Gestational Diabetes; Metformin; Pregnant women; Systematic review. Abstract Gestational Diabetes Mellitus is a condition characterized by an increase in blood glucose levels, which can be initiated or diagnosed during pregnancy. This process occurs due to the production of high levels of hormones by the placenta, most of which are harmful to the action of insulin in the cells increasing the blood sugar level and can affect the growth

2020 Research, Society and Development

16. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. (Abstract)

Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Metformin has been proposed as possibly a safer and more effective long-term treatment than the oral contraceptive pill (OCP) in women with polycystic ovary syndrome (PCOS). It is important to directly compare the efficacy and safety of metformin versus OCP in the long-term treatment of women with PCOS. This is an update of a Cochrane Review comparing insulin (...) sensitising agents with the OCP and only includes studies on metformin.To assess the effectiveness and safety of metformin versus the OCP (alone or in combination) in improving clinical, hormonal, and metabolic features of PCOS.In August 2019 we searched the Cochrane Gynaecology and Fertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and CINAHL, the trial registers, handsearched references of the identified articles, and contacted experts in the field

2020 Cochrane

17. Efficacy of metformin in patients with breast cancer receiving chemotherapy or endocrine therapy:Systematic review and meta-analysis (protocol) v1 (protocols.io.bijpkcmn) Full Text available with Trip Pro

Efficacy of metformin in patients with breast cancer receiving chemotherapy or endocrine therapy:Systematic review and meta-analysis (protocol) v1 (protocols.io.bijpkcmn) Efficacy of metformin in patients with breast cancer receiving chemotherapy or endocrine therapy:Systematic review and meta-analysis (protocol) protocols.io

2020 protocols.io

18. Metformin monotherapy for adults with type 2 diabetes mellitus. Full Text available with Trip Pro

Metformin monotherapy for adults with type 2 diabetes mellitus. Worldwide, there is an increasing incidence of type 2 diabetes mellitus (T2DM). Metformin is still the recommended first-line glucose-lowering drug for people with T2DM. Despite this, the effects of metformin on patient-important outcomes are still not clarified.To assess the effects of metformin monotherapy in adults with T2DM.We based our search on a systematic report from the Agency for Healthcare Research and Quality (...) , and topped-up the search in CENTRAL, MEDLINE, Embase, WHO ICTRP, and ClinicalTrials.gov. Additionally, we searched the reference lists of included trials and systematic reviews, as well as health technology assessment reports and medical agencies. The date of the last search for all databases was 2 December 2019, except Embase (searched up 28 April 2017).We included randomised controlled trials (RCTs) with at least one year's duration comparing metformin monotherapy with no intervention, behaviour

2020 Cochrane

19. Metformin may reduce the mortality and cardiac events in patients with cardio-cerebrovascular diseases, irrespective of concurrent diabetes: a meta-analysis of randomized controlled trails and cohort studies Full Text available with Trip Pro

Metformin may reduce the mortality and cardiac events in patients with cardio-cerebrovascular diseases, irrespective of concurrent diabetes: a meta-analysis of randomized controlled trails and cohort studies Inplasy Protocol 358 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

20. Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB) Full Text available with Trip Pro

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB) Comparison of Tofogliflozin Versus Glimepiride as the Third Oral Agent Added to Metformin Plus a Dipeptidyl peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes: A Randomized, 24-week, Open-Label, Controlled Trial (STOP-OB) - PubMed This site needs (...) to Metformin Plus a Dipeptidyl peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes: A Randomized, 24-week, Open-Label, Controlled Trial (STOP-OB) , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. 2 Seino Internal Medicine Clinic, Koriyama, Japan. 3 Internal Medicine, Oyama East Clinic, Oyama, Japan. 4 Department

2020 EvidenceUpdates